-
821
Advancements and Challenges in Immune Protection Strategies for Islet Transplantation
Published 2025-01-01“…However, the limited availability of human cadaveric islet donors and the need for ongoing administration of immunosuppressive agents post‐transplantation hinder the widespread use of this treatment. …”
Get full text
Article -
822
Isolated Sporothrix schenckii Monoarthritis
Published 2018-01-01“…In patients with underlying risk factors (HIV, alcoholism, diabetes mellitus, organ transplant patients, immunosuppressive medications, steroids, and malignancies), it can often have disseminated visceral, osteoarticular, meningeal, and pulmonary involvement. …”
Get full text
Article -
823
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy
Published 2025-02-01“…These bottlenecks include low in vivo persistence, low trafficking into tumor sites, modest efficacy in solid tumors, and sensitivity to immunosuppressive tumor microenvironment. In recent years, advances in gene manipulation tools and strategies have laid the groundwork to overcome the current bottlenecks of CAR-NK cell therapy. …”
Get full text
Article -
824
An Unusual Initial Presentation of Lupus Nephritis as a Renal Mass
Published 2015-01-01“…A diagnosis of probable silent lupus nephritis was made and the patient was followed up without immunosuppressive treatment. After two years of follow-up, she did not progress to overt disease. …”
Get full text
Article -
825
Fatal Epstein-Barr Virus Reactivation in an Acquired Aplastic Anemia Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine A
Published 2015-01-01“…Epstein-Barr virus (EBV) associated lymphoproliferative disorder (LPD) after immunosuppressive therapy for aplastic anemia (AA) is extremely rare in a nontransplant setting and has not been well described. …”
Get full text
Article -
826
RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation
Published 2025-02-01“…Abstract Applying CAR T-cell therapy to treat solid tumors is especially challenging due to the immunosuppressive tumor microenvironment (TME). While our modular RevCAR system enhances the safety and controllability of CAR T-cell therapy, effectively targeting solid tumors remains difficult. …”
Get full text
Article -
827
A Case of Systemic Lupus Erythematosus/Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome with Dissociated Pathological and Immunological Findings
Published 2020-01-01“…SLE/AAV OS was suspected, we started immunosuppressant therapy, and subsequently her renal function improved. …”
Get full text
Article -
828
The Pathology of T Cells in Systemic Lupus Erythematosus
Published 2014-01-01“…Lastly, while currently available outcomes of clinical trials evaluating therapeutic agents which manipulate the T cells such as calcineurin inhibitors indicate that they are at least as efficacious and safe as conventional immunosuppressants in treating lupus glomerulonephritis, larger clinical trials are undoubtedly required to validate these as-yet favourable findings.…”
Get full text
Article -
829
AIDS Cholangiopathy in an Asymptomatic, Previously Undiagnosed Late-Stage HIV-Positive Patient from Kenya
Published 2011-01-01“…AIDS-associated cholangiopathy is a form of biliary tract inflammation with stricture formation seen in AIDS patients who are severely immunosuppressed. It is no longer common in countries in which HAART therapy is widely employed but is still seen in underdeveloped countries. …”
Get full text
Article -
830
Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy
Published 2020-01-01“…Moreover, the impact of nanoparticles on the immunosuppressive behavior of tumor environment has been discussed. …”
Get full text
Article -
831
Identifying Safeguards Disabled by Epstein-Barr Virus Infections in Genomes From Patients With Breast Cancer: Chromosomal Bioinformatics Analysis
Published 2025-01-01“…EBV-transformed human mammary cells accelerate breast cancer when transplanted into immunosuppressed mice, but the virus can disappear as malignant cells reproduce. …”
Get full text
Article -
832
Update on Primary Biliary Cirrhosis
Published 2000-01-01“…Treatment includes symptomatic and preventive measures, as well as specific therapeutic measures. Immunosuppressive therapy has yielded disappointing results in the long term management of PBC, and the only therapy shown to improve survival is the hydrophobic dihydroxy bile acid ursodeoxycholic acid. …”
Get full text
Article -
833
SDZ MRL 953, A Novel Synthetic Lipid a Analogue, Induces Tolerance to the Lethal Effects of Endotoxin and Enhances Nonspecific Immunity
Published 1992-01-01“…Despite the availability of potent antimicrobials, shock due to Gram-negative rod sepsis remains an important clinical concern in immunosuppressed patients. Current strategies for treating septic shock by removal of endotoxin (lipopolysaccharides [LPS]) or putative mediators have only been partially effective. …”
Get full text
Article -
834
Cell-Type-Specific Differentiation and Molecular Profiles in Skin Transplantation: Implication of Medical Approach for Genetic Skin Diseases
Published 2011-01-01“…These local events are more unlikely to be regulated by the host immunity, because human skin transplantation has accomplished the donor skin engraftment onto the immunocompromised or immunosuppressive animals. Recent studies have emerged the importance of α-smooth muscle actin- (SMA-) positive myofibroblasts, via stage- and cell-specific contribution of TGFβ, PDGF, ET-1, CCN-2 signalling pathways, and mastocyte-derived mediators (e.g., histamine and tryptase), for the functional reorganisation of the grafted skin. …”
Get full text
Article -
835
Immunotherapy Responsive Autoimmune Subacute Encephalitis: A Report of Two Cases
Published 2010-01-01“…It is important to screen patients with subacute encephalitis for anti-TPO antibody and VGKCAb, particularly in the presence of seizures. Immunosuppressive therapy appears to be effective in treating this entity.…”
Get full text
Article -
836
Rhodotorula mucilaginosa Fungemia, a Rare Opportunistic Infection without Central Venous Catheter Implantation, Successfully Treated by Liposomal Amphotericin B
Published 2022-01-01“…Although the obvious entry point was unclear, long-term immunosuppressive therapy for RA may have damaged the gastrointestinal tract, which leading to the bacterial translocation of R. mucilaginosa. …”
Get full text
Article -
837
Recognizing Immunoglobulin G4-Related Overlap Syndromes in Patients with Pancreatic and Hepatobiliary Diseases
Published 2008-01-01“…In the first instance, patients generally have a dramatic response to immunosuppressive therapy, whereas patients with other forms of cholangitis and pancreatitis do not. …”
Get full text
Article -
838
Wilson’s Disease and Autoimmune Hepatitis Coexistence: A Cause of Diagnostic Delay
Published 2023-09-01“…A chelating agent, D penicillamine, was added to her immunosuppressive treatment. Nine months later she showed slow improvement in her neurological symptoms and was referred for assessment for liver transplantation. …”
Get full text
Article -
839
Update on Babesiosis
Published 2009-01-01“…People over the age of 50 years and immunocompromised individuals are at the highest risk of severe disease, including those with malignancy, HIV, lacking a spleen, or receiving immunosuppressive drugs. Asymptomatic carriers present a blood safety risk when they donate blood. …”
Get full text
Article -
840
Late Relapse of Previous Pulmonary Cryptococcosis With Symptoms Resembling Cerebral Infarction: A Case Report
Published 2024-01-01“…The disease can also occur in individuals with various immunosuppressive conditions, frequently involving the brain or lungs. …”
Get full text
Article